Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by ectopic endometrial-like glands and stroma, persistent pelvic inflammation, pain, infertility, and frequent recurrence. The limited availability of nonhormonal and lesion-directed therapies …
Endometriosis is a chronic inflammatory disease characterized by substantial heterogeneity in pain, lesion behavior, and treatment response. Although hormonal and surgical therapies can reduce disease activity and symptoms, their effects …
Endometriosis is a chronic inflammatory disease characterised by pain, infertility and recurrence. Current pharmacological management relies largely on hormonal suppression, which can reduce pain and disease activity but does not …
β-Glucuronidase (β-G, EC 3.2.1.31) reverses phase II glucuronidation, and microbial β-G at the gut-liver interface reactivates biliary and circulating conjugates, closing enterohepatic loops for drugs, estrogens, bile acids, and bilirubin. …
Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …
Endometriosis affects approximately one in seven women in Australia and is associated with substantial physical, psychological and social impacts. Informational support is critical for enabling informed decision-making and fostering women's …
Endometriosis is frequently associated with impaired fertility. Metabolic abnormalities and dyslipidemia may be relevant to reproductive dysfunction among women with endometriosis; however, their associations with subsequent reproductive outcomes and their …
Hepatic endometriosis is a rare extrapelvic manifestation that can mimic hepatic neoplasia and, exceptionally, cause hemoperitoneum. We report a 45-year-old nulligravid woman with longstanding deep endometriosis and anticoagulation for cavoiliac …
Endometriosis (EuE) is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, nonhormonal therapies is urgently needed. …
Decisions about healthcare funding and delivery in Aotearoa New Zealand, as well as the monitoring of health service performance and outcomes, are driven by readily available data, in particular from …